Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity.
Sign Up to like & getrecommendations! Published in 2018 at "JCI insight"
DOI: 10.1172/jci.insight.96753
Abstract: Anthracyclines such as doxorubicin are highly effective chemotherapy agents used to treat many common malignancies. However, their use is limited by cardiotoxicity. We previously identified visnagin as protecting against doxorubicin toxicity in cardiac but not… read more here.
Keywords: highly potent; visnagin; doxorubicin cardiotoxicity; potent visnagin ... See more keywords
Therapeutic Potential of Albumin Nanoparticles Encapsulated Visnagin in MDA-MB-468 Triple-Negative Breast Cancer Cells
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28073228
Abstract: Breast cancer is among the most recurrent malignancies, and its prevalence is rising. With only a few treatment options available, there is an immediate need to search for better alternatives. In this regard, nanotechnology has… read more here.
Keywords: visnagin; microscopy; mda 468; breast cancer ... See more keywords
NIPAAm-MMA nanoparticle-encapsulated visnagin ameliorates myocardial ischemia/reperfusion injury through the promotion of autophagy and the inhibition of apoptosis
Sign Up to like & getrecommendations! Published in 2018 at "Oncology Letters"
DOI: 10.3892/ol.2018.7922
Abstract: The main method for the treatment of acute myocardial infarction (AMI) is percutaneous coronary intervention; however percutaneous coronary intervention will induce ischemia/reperfusion (IR) injury, resulting in the loss of cardiac function and cardiomyocyte death. An… read more here.
Keywords: autophagy inhibition; visnagin; ischemia reperfusion; reperfusion injury ... See more keywords